OM:IBT B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Infant Bacterial Therapeutics

Executive Summary

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Infant Bacterial Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IBT B's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.4%

IBT B

2.0%

SE Pharmaceuticals

3.9%

SE Market


1 Year Return

-54.1%

IBT B

6.1%

SE Pharmaceuticals

11.2%

SE Market

Return vs Industry: IBT B underperformed the Swedish Pharmaceuticals industry which returned 3.5% over the past year.

Return vs Market: IBT B underperformed the Swedish Market which returned 9.4% over the past year.


Shareholder returns

IBT BIndustryMarket
7 Day-4.4%2.0%3.9%
30 Day0.2%5.0%13.1%
90 Day-3.1%17.6%4.0%
1 Year-54.1%-54.1%10.8%6.1%12.8%11.2%
3 Year31.1%17.3%30.5%15.9%17.5%1.6%
5 Yearn/a23.3%-2.2%36.5%9.7%

Price Volatility Vs. Market

How volatile is Infant Bacterial Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Infant Bacterial Therapeutics undervalued compared to its fair value and its price relative to the market?

2.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IBT B's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IBT B's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IBT B is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: IBT B is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IBT B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IBT B is good value based on its PB Ratio (2.3x) compared to the SE Pharmaceuticals industry average (3.9x).


Next Steps

Future Growth

How is Infant Bacterial Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

43.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Infant Bacterial Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Infant Bacterial Therapeutics performed over the past 5 years?

-25.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IBT B is currently unprofitable.

Growing Profit Margin: IBT B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IBT B is unprofitable, and losses have increased over the past 5 years at a rate of -25.8% per year.

Accelerating Growth: Unable to compare IBT B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBT B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.5%).


Return on Equity

High ROE: IBT B has a negative Return on Equity (-8.69%), as it is currently unprofitable.


Next Steps

Financial Health

How is Infant Bacterial Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: IBT B's short term assets (SEK510.4M) exceed its short term liabilities (SEK11.6M).

Long Term Liabilities: IBT B has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IBT B is debt free.

Reducing Debt: IBT B has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IBT B has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IBT B has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.6% each year


Next Steps

Dividend

What is Infant Bacterial Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IBT B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IBT B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IBT B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBT B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IBT B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Staffan Strömberg (52yo)

7.42yrs

Tenure

kr3,224,000

Compensation

Mr. Staffan Strömberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Strömberg serves as Vice President of Development and Regulatory Affairs at  ...


CEO Compensation Analysis

Compensation vs Market: Staffan's total compensation ($USD345.12K) is above average for companies of similar size in the Swedish market ($USD221.38K).

Compensation vs Earnings: Staffan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Staffan Strömberg
Chief Executive Officer7.42yrskr3.22m0.78% SEK9.2m
Anders Kronström
Chief Operating Officer2.42yrskr500.00k0.028% SEK332.9k
Eamonn Connolly
Head of R&D and Chief Scientific Officer2.83yrskr150.00k0.51% SEK6.0m
Daniel Mackey
Chief Financial Officer3.42yrskr1.65m0.055% SEK642.7k
Jonas Rastad
Chief Medical Officer2.08yrsno datano data

2.8yrs

Average Tenure

52yo

Average Age

Experienced Management: IBT B's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Rothschild
Chairman9.42yrskr600.00kno data
Margareta Hagman
Independent Director4.75yrskr100.00k0.032% SEK374.8k
Eva Idén
Independent Director3.08yrskr100.00k0.00027% SEK3.2k
Kristina Nygren
Independent Director2.08yrskr100.00kno data
Anthon Jahreskog
Independent Director3.08yrskr100.00kno data

3.1yrs

Average Tenure

53yo

Average Age

Experienced Board: IBT B's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Infant Bacterial Therapeutics AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Infant Bacterial Therapeutics AB (publ)
  • Ticker: IBT B
  • Exchange: OM
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr1.179b
  • Shares outstanding: 11.23m
  • Website: https://www.ibtherapeutics.com

Number of Employees


Location

  • Infant Bacterial Therapeutics AB (publ)
  • Bryggargatan 10
  • Stockholm
  • Stockholm County
  • 111 21
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IBT BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKMar 2016
9IBBST (Boerse-Stuttgart)YesClass B SharesDEEURMar 2016
IBTBSBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBSEKMar 2016

Biography

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 00:20
End of Day Share Price2020/06/03 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.